[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553676":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":18,"responsibleParty":31,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":40,"conditions":48,"keywords":7,"overallStatus":50,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Zanubrutinib","patients with treatment naive or R\u002FR CLL who treatment with Zanubrutinib",[14],{"name":15,"role":16,"phone":7,"phoneExt":7,"email":17},"Shenmiao Yang","CONTACT","yangshenmiao@hotmail.com",[19],{"facility":5,"status":7,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":7},"Beijing","Beijing Municipality","100044","China","CN",{"type":26,"coordinates":27},"Point",[28,29],116.39723,39.9075,{"lat":29,"lon":28},{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Xiao-Jun Huang","Prof.","100553676","the-real-world-study-of-zanubrutinib-in-the-treatment-of-chronic-lymphocytic-leukemia-in-china-100553676",false,"NCT06489184","The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China","This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China","Inclusion Criteria:\n\n* 1\\. Patients aged ≥18 years old\n* 2\\. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \\[International Workshop on Chronic Lymphocytic Leukemia\\] criteria)；\n* 3\\. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;\n* 4.Prior or current use of Zanubrutinib for ≥3 months\n* 5.At least one follow-up was recorded during Zanubrutinib treatment\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":45,"type":46},490,"ESTIMATED","OBSERVATIONAL",[49],"CLL","NOT_YET_RECRUITING","2024-06-28",{"date":53,"type":54},"2024-07-05","ACTUAL",{"date":56,"type":46},"2024-08-01",{"date":58,"type":46},"2025-12-30",{"name":5,"class":6},1]